Gene · 7278
TUBA3C: tubulin alpha 3c
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBA3C: tubulin alpha 3c. Genes, record 7278. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7278
On this page
Gene
Proteins2
Reviewed human proteins whose Swiss-Prot entry states the gene.
Patents78
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 12372 | P0DPH7 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 12372 | P0DPH8 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 12372 | P0DPH7 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 12372 | P0DPH8 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5432 | P0DPH7 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5432 | P0DPH8 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 7066 | P0DPH7 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 7066 | P0DPH8 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93557 | P0DPH7 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93557 | P0DPH8 | Espacenet |
1 to 10 of 78
See all 78 patentsDrugs90
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BIIB-015 | CHEMBL2109575 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 90
See all 90 drugsTrials8,728
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,728
See all 8,728 trialsNIH grants181
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBA3C papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 2 | 2025 |
| P50HD096723 | Genetics of Male Infertility: Accelerating the pace of discovery | 2 | 2025 |
| R01HD078641 | Genomics of spermatogenic impairment | 2 | 2025 |
| K12GM093854 | IRACDA at Rutgers: INSPIRE Postdoctoral Training Program | 1 | 2025 |
| K12HD000850 | Pediatric Scientist Development Program | 1 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 1 | 2025 |
| P30CA069533 | OHSU Knight Cancer Institute | 1 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 1 | 2025 |
1 to 10 of 181Source NIH's project files
See all 181 nih grantsPapers236
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection. | Res Sq | 2026 | 41756461 | PubTator, text mining | PubMed |
| Multiomics approaches in Kawasaki disease: insights into pathogenesis and emerging directions for diagnosis and treatment. | Clin Exp Pediatr | 2026 | 41736230 | PubTator, text mining | PubMed |
| Genome-wide association study of corneal dystrophy uncovers novel risk loci and enables improved polygenic prediction of Fuchs endothelial corneal dystrophy. | medRxiv | 2026 | 41728327 | PubTator, text mining | PubMed |
| Planarian microtubules form a network within muscle and regulate injury-induced genes essential for regeneration patterning. | Development | 2025 | 41099309 | PubTator, text mining | PubMed |
| Machine learning-based identification of diagnostic and prognostic mitotic cell cycle genes in hepatocellular carcinoma. | PLoS One | 2025 | 40875626 | PubTator, text mining | PubMed |
| Glucosylsphingosine affects mitochondrial function in a neuronal cell model. | Commun Biol | 2025 | 40841705 | PubTator, text mining | PubMed |
| Age-Associated Proteomic Changes in Human Spermatozoa. | Int J Mol Sci | 2025 | 40649876 | PubTator, text mining | PubMed |
| Identification of Novel Biomarkers Related to Vesicle Trafficking in Alzheimer's Disease Using Bioinformatics Approaches. | Neurochem Res | 2025 | 40338387 | PubTator, text mining | PubMed |
| Genome sequencing of Pakistani families with male infertility identifies deleterious genotypes in SPAG6, CCDC9, TKTL1, TUBA3C, and M1AP. | Andrology | 2025 | 38073178 | PubTator, text mining | PubMed |
| The Rogdi knockout mouse is a model for Kohlschütter-Tönz syndrome. | Sci Rep | 2024 | 38172607 | PubTator, text mining | PubMed |
1 to 10 of 236
See all 236 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7278
GET https://conductscience.org/api/genes/v1/7278/patents?page=2